Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

American Healthcare REIT (AHR) Gains from Sales and Divestitures (2024 - 2026)

American Healthcare REIT filings provide 2 years of Gains from Sales and Divestitures readings, the most recent being $158889.0 for Q4 2025.

On a quarterly basis, Gains from Sales and Divestitures rose 194.18% to $158889.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $158889.0, a 194.18% increase, with the full-year FY2025 number at $158889.0, up 194.18% from a year prior.
Gains from Sales and Divestitures hit $158889.0 in Q4 2025 for American Healthcare REIT, down from $244087.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $244087.0 in Q3 2025 to a low of $54010.0 in Q4 2024.